Spreading its geographic wings further, in the face of ongoing difficulties in China, UK pharma major AstraZeneca (LSE: AZN) has announced a C$820 million (US$570 million) investment in Canada, creating more than 700 high-skilled jobs, across all areas of the business.
AstraZeneca noted that the investment will support the move to a larger, state-of-the-art office facility in the Greater Toronto Area (GTA), Ontario.
New investment in Canada will contribute to AstraZeneca’s global ambition to achieve $80 billion in total revenue and to bring 20 new medicines to patients around the world by 2030 of which eight new medicines have been delivered to date. The company also expects seven first Phase III clinical trial data readouts in 2025.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze